SCHEMBL7072235

SCHEMBL7072235

COC(=O)CCc1cc(Br)sc1Br

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TSHR P16473 2/20 0.40
RPS6KB2 Q9UBS0 1/20 0.39
KAT2B Q92831 1/20 0.39
HPGD P15428 2/20 0.38
KMT2A Q03164 3/20 0.38
ALDH1A1 P00352 2/20 0.38
LMNA P02545 2/20 0.38
MAPT P10636 2/20 0.38
HTT P42858 1/20 0.38
HSD17B10 Q99714 1/20 0.38
EGFR P00533 1/20 0.37
CCNC P24863 1/20 0.36
CDK8 P49336 1/20 0.36
MEN1 O00255 2/20 0.36
L3MBTL1 Q9Y468 2/20 0.36
CYP1A2 P05177 1/20 0.36
ATM Q13315 1/20 0.36
CYP11B1 P15538 1/20 0.35
CYP11B2 P19099 1/20 0.35
IDO1 P14902 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21054355 0.84 HSP90AB1 (0.42) TSHRKAT2BHPGDKMT2AALDH1A1
SCHEMBL17533163 0.83 CYP4F2 (0.50) KAT2BALDH1A1MAPTCYP1A2GAA
SCHEMBL14645460 0.80 RPS6KB2 (0.43) TSHRRPS6KB2KAT2BHPGDKMT2A
SCHEMBL15774072 0.78 NPSR1 (0.48) HPGDLMNAMAPTL3MBTL1
SCHEMBL18050370 0.77 IAPP (0.44) ALDH1A1MAPTL3MBTL1
SCHEMBL29147854 0.77 GSK3B (0.35) MAPTL3MBTL1
SCHEMBL1569441 0.75 TNKS2 (0.36) TSHRALDH1A1HTTGAA
SCHEMBL5007610 0.74 CYP4F2 (0.48) KAT2BCYP1A2
SCHEMBL14645332 0.74 HSP90AB1 (0.42) TSHRKAT2BHPGDKMT2AALDH1A1
SCHEMBL31176880 0.73 RPS6KB2 (0.38) TSHRRPS6KB2KAT2BHPGDKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1318979-A1 CYCLOPENTANE DERIVATIVES AS THERAPEUTIC AGENTS Allergan Sales, Inc. (US) 2003-06-18 EP disclosed
WO-2002024639-A1 CYCLOPENTANE DERIVATIVES AS THERAPEUTIC AGENTS ALLERGAN, INC. (US) 2002-03-28 WO disclosed
US-6359181-B1 THERAPY FOR VISION DEFECTS ALLERGAN SALES, INC. 2002-03-19 US disclosed
US-6307092-B1 POTENT OCULAR HYPOTENSIVES AND ARE PARTICULARLY SUITED FOR THE MANAGEMENT OF GLAUCOMA. ALLERGAN SALES, INC. 2001-10-23 US disclosed
US-6248783-B1 GLAUCOMA THERAPY ALLERGAN SALES, INC. 2001-06-19 US disclosed